3 studies found for:    20299316 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
Conditions: Metastatic Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Intervention: Drug: Bevacizumab and eribulin
2 Active, not recruiting
Has Results
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Condition: Metastatic Breast Cancer
Interventions: Drug: Eribulin Mesylate;   Drug: Capecitabine
3 Completed
Has Results
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: E7389;   Drug: Physician's Choice

Indicates status has not been verified in more than two years